Price$2.78+0.07 (+2.58%)
01:30 PM07:45 PM
News · 26 weeks240%
2025-11-022026-04-26
Mix1290d
- SEC Filings7(58%)
- Other5(42%)
Latest news
25 items- SECSEC Form DEFA14A filed by Nkarta Inc.DEFA14A - Nkarta, Inc. (0001787400) (Filer)
- SECSEC Form DEF 14A filed by Nkarta Inc.DEF 14A - Nkarta, Inc. (0001787400) (Filer)
- PRNkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology CentersExpanded treatment in community settings will reduce patient burdenOption to redose patients granted in both Ntrust-1 and Ntrust-2 studiesRheumatoid arthritis cohort to be added to Ntrust-2Dosing continues at 4 billion cell dose level (12 billion cells in 3-dose cycle) with initial data expected to be presented at a medical meeting this year SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on key changes to the ongoing Ntrust-1
- PRNkarta to Participate in Needham Virtual Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference. At 11:45 a.m. ET on Wednesday, April 15, Nkarta CEO Paul Hastings will participate in a virtual panel discussion, "Cell Therapy in Autoimmune: State of the Art and What Comes Next." Later that afternoon, Nkarta President Nadir Mahmood will participate in a 3:45 p.m ET fireside chat to share updates on the company's investigational CAR-NK cell therapy to treat B cell-mediated auto
- SECSEC Form EFFECT filed by Nkarta Inc.EFFECT - Nkarta, Inc. (0001787400) (Filer)
- SECSEC Form 424B5 filed by Nkarta Inc.424B5 - Nkarta, Inc. (0001787400) (Filer)
- SECSEC Form S-3 filed by Nkarta Inc.S-3 - Nkarta, Inc. (0001787400) (Filer)
- SECSEC Form 10-K filed by Nkarta Inc.10-K - Nkarta, Inc. (0001787400) (Filer)
- SECNkarta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nkarta, Inc. (0001787400) (Filer)
- PRNkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate HighlightsDose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycleInitial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation at a medical conference in 2026Cash balance of $295.1 million on December 31, 2025, including cash, cash equivalents and investments, is expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the fourth quarter and year ended December 31, 2025. "2025 was a ye
- PRNkarta to Participate in March Investor ConferencesSOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences: March 2, 2026TD Cowen 46th Annual Health Care ConferenceBoston, MA9:10 a.m. EST – fireside chatMarch 10, 2026Leerink Global Healthcare ConferenceMiami, FL10:40 a.m. EDT – fireside chatA simultaneous webcast of both events will be available on the Investors section of Nkarta's website, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biote
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Nkarta Inc.SCHEDULE 13G/A - Nkarta, Inc. (0001787400) (Subject)
- INSIDERChief Executive Officer Hastings Paul J sold $53,915 worth of shares (26,046 units at $2.07), decreasing direct ownership by 6% to 390,023 units (SEC Form 4)4 - Nkarta, Inc. (0001787400) (Issuer)
- INSIDERPresident Mahmood Nadir sold $11,693 worth of shares (5,649 units at $2.07), decreasing direct ownership by 3% to 167,727 units (SEC Form 4)4 - Nkarta, Inc. (0001787400) (Issuer)
- INSIDEROfficer Rose Shawn Marshall was granted 70,000 shares (SEC Form 4)4 - Nkarta, Inc. (0001787400) (Issuer)
- INSIDERPresident Mahmood Nadir was granted 80,000 shares, increasing direct ownership by 86% to 173,376 units (SEC Form 4)4 - Nkarta, Inc. (0001787400) (Issuer)
- INSIDERChief Executive Officer Hastings Paul J was granted 94,000 shares, increasing direct ownership by 29% to 416,069 units (SEC Form 4)4 - Nkarta, Inc. (0001787400) (Issuer)
- SECSEC Form S-8 filed by Nkarta Inc.S-8 - Nkarta, Inc. (0001787400) (Filer)
- PRNkarta to Participate in Evercore Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami. Evercore 8th Annual Healthcare ConferenceDecember 4, 202510:50 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Nkarta Inc.SCHEDULE 13D/A - Nkarta, Inc. (0001787400) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Nkarta Inc.SCHEDULE 13G/A - Nkarta, Inc. (0001787400) (Subject)
- SECSEC Form 10-Q filed by Nkarta Inc.10-Q - Nkarta, Inc. (0001787400) (Filer)
- SECNkarta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nkarta, Inc. (0001787400) (Filer)
- PRNkarta Reports Third Quarter 2025 Financial Results and Corporate HighlightsEnrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamideEnrollment streamlined across Ntrust-1 and Ntrust-2 under a combined independent Data Safety Monitoring Board (iDSMB) to guide dose escalation Initial data for NKX019 in multiple autoimmune indications expected to be presented at a medical conference in 2026Cash balance of $316.5 million on September 30, 2025, including cash, cash equivalents, and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Ca
- PRNkarta to Participate in November Investor ConferencesSOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month: Stifel 2025 Healthcare ConferenceNovember 12, 202510:40 a.m. ET – fireside chat TD Cowen's Immunology & Inflammation SummitNovember 13, 20255 p.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company a
NKTX FAQ
7 questionsWhat does Nkarta Inc. do?
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which...Where does NKTX stock trade?
Nkarta Inc. (NKTX) is listed on NASDAQ.What sector and industry is NKTX in?
Nkarta Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nkarta Inc. go public?
Nkarta Inc. (NKTX) completed its IPO in 2020.What are analysts saying about NKTX?
Nkarta Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Mkt Perform on 2025-05-15. Recent price targets range from $1400.00 to $3000.00.What companies are similar to NKTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare NKTX side-by-side with any of them on Quantisnow.How can I track NKTX on Quantisnow?
Quantisnow aggregates Nkarta Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NKTX to receive live email and push alerts on every new disclosure.